Developing an inhaled treatment for COVID-19 and similar infections
SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections
['FUNDING_SBIR_2'] · INHALON BIOPHARMA, INC. · NIH-11046650
This study is testing a new inhaled treatment for COVID-19 that uses special antibodies to help trap and remove the virus from your airways, making it easier for you to use at home and potentially keeping you out of the hospital.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INHALON BIOPHARMA, INC. (nih funded) |
| Locations | 1 site (Morrisville, UNITED STATES) |
| Trial ID | NIH-11046650 on ClinicalTrials.gov |
What this research studies
This research focuses on creating an inhaled immunotherapy that targets COVID-19 and other infections by using muco-trapping antibodies. These antibodies are designed to be delivered directly to the airways through handheld nebulizers, allowing for easy self-administration at home. The approach aims to effectively trap and remove the virus from the airway mucus, potentially reducing the risk of hospitalization and retaining effectiveness against various virus variants. The treatment is designed to avoid drug-drug interactions, making it a safer option for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at risk of severe COVID-19 or have difficulty accessing traditional treatments.
Not a fit: Patients who are not infected with COVID-19 or those who have already received effective treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for COVID-19 that is easy to use and minimizes hospitalization risks.
How similar studies have performed: While inhaled therapies for respiratory infections are being explored, this specific approach using muco-trapping antibodies is novel and has not been widely tested.
Where this research is happening
Morrisville, UNITED STATES
- INHALON BIOPHARMA, INC. — Morrisville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HUTCHINS, JEFF T — INHALON BIOPHARMA, INC.
- Study coordinator: HUTCHINS, JEFF T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Airway infections